IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025
IO Biotech (Nasdaq: IOBT) has been recognized as the 9th most innovative company in biotechnology on Fast Company's World's Most Innovative Companies of 2025 list. The clinical-stage biopharmaceutical company earned this distinction for its innovative approach to immune-modulatory cancer vaccines.
The company's T-win® platform develops off-the-shelf therapeutic cancer vaccines designed to target and kill both tumor cells and immune-suppressive cells in the tumor microenvironment. Their lead candidate, Cylembio®, is currently in:
- A global Phase 3 trial for advanced melanoma with primary endpoint readout expected in Q3 2025
- Phase 2 trials combining with pembrolizumab for non-small cell lung cancer and head and neck cancer
- Phase 2 trials as neoadjuvant and adjuvant treatment for resectable melanoma and head and neck cancer
The recognition by Fast Company highlights IO Biotech's potential to transform the oncology treatment paradigm with products designed to be available at diagnosis.
IO Biotech (Nasdaq: IOBT) è stata riconosciuta come la nona azienda più innovativa nel settore della biotecnologia nella lista World's Most Innovative Companies of 2025 di Fast Company. L'azienda biofarmaceutica in fase clinica ha ottenuto questo riconoscimento per il suo approccio innovativo ai vaccini contro il cancro modulanti l'immunità.
La piattaforma T-win® dell'azienda sviluppa vaccini terapeutici contro il cancro pronti all'uso, progettati per mirare e uccidere sia le cellule tumorali che le cellule immunosoppressive presenti nel microambiente tumorale. Il loro candidato principale, Cylembio®, è attualmente in:
- Una sperimentazione globale di Fase 3 per il melanoma avanzato, con la lettura del risultato primario prevista per il terzo trimestre del 2025
- Sperimentazioni di Fase 2 in combinazione con pembrolizumab per il cancro polmonare non a piccole cellule e il cancro testa-collo
- Sperimentazioni di Fase 2 come trattamento neoadiuvante e adiuvante per melanoma e cancro testa-collo resecabili
Il riconoscimento da parte di Fast Company sottolinea il potenziale di IO Biotech di trasformare il paradigma del trattamento oncologico con prodotti progettati per essere disponibili al momento della diagnosi.
IO Biotech (Nasdaq: IOBT) ha sido reconocida como la novena empresa más innovadora en biotecnología en la lista de Fast Company World's Most Innovative Companies of 2025. La empresa biofarmacéutica en etapa clínica obtuvo esta distinción por su enfoque innovador en las vacunas contra el cáncer moduladoras de la inmunidad.
La plataforma T-win® de la compañía desarrolla vacunas terapéuticas contra el cáncer listas para usar, diseñadas para atacar y eliminar tanto las células tumorales como las células inmunosupresoras en el microambiente tumoral. Su candidato principal, Cylembio®, se encuentra actualmente en:
- Un ensayo global de Fase 3 para melanoma avanzado, con la lectura del punto final primario esperada para el tercer trimestre de 2025
- Ensayos de Fase 2 combinados con pembrolizumab para cáncer de pulmón no microcítico y cáncer de cabeza y cuello
- Ensayos de Fase 2 como tratamiento neoadyuvante y adyuvante para melanoma y cáncer de cabeza y cuello resecables
El reconocimiento por parte de Fast Company destaca el potencial de IO Biotech para transformar el paradigma del tratamiento oncológico con productos diseñados para estar disponibles en el momento del diagnóstico.
IO Biotech (Nasdaq: IOBT)는 Fast Company의 2025년 세계에서 가장 혁신적인 기업 목록에서 생명공학 분야에서 9위로 선정되었습니다. 이 임상 단계의 생물약제 회사는 면역 조절 암 백신에 대한 혁신적인 접근 방식으로 이 영예를 얻었습니다.
회사의 T-win® 플랫폼은 종양 세포와 종양 미세 환경의 면역 억제 세포를 표적으로 하여 죽이도록 설계된 즉시 사용할 수 있는 치료용 암 백신을 개발합니다. 그들의 주요 후보인 Cylembio®는 현재:
- 3상 글로벌 임상 시험 중으로, 진행성 흑색종에 대한 주요 결과는 2025년 3분기에 발표될 예정입니다.
- 비소세포 폐암 및 두경부암에 대한 pembrolizumab과의 병용 2상 임상 시험 중입니다.
- 절제 가능한 흑색종 및 두경부암에 대한 신보조 및 보조 치료로서의 2상 임상 시험 중입니다.
Fast Company의 인식은 IO Biotech의 진단 시점에서 사용할 수 있도록 설계된 제품으로 종양학 치료 패러다임을 변화시킬 수 있는 잠재력을 강조합니다.
IO Biotech (Nasdaq: IOBT) a été reconnue comme la neuvième entreprise la plus innovante dans le domaine de la biotechnologie dans la liste World's Most Innovative Companies of 2025 de Fast Company. L'entreprise biopharmaceutique en phase clinique a obtenu cette distinction pour son approche innovante des vaccins contre le cancer modulant l'immunité.
La plateforme T-win® de l'entreprise développe des vaccins thérapeutiques contre le cancer prêts à l'emploi, conçus pour cibler et éliminer à la fois les cellules tumorales et les cellules immunosuppressives dans le microenvironnement tumoral. Leur candidat principal, Cylembio®, est actuellement en :
- Un essai mondial de phase 3 pour le mélanome avancé, avec la lecture du critère principal attendue au troisième trimestre 2025
- Des essais de phase 2 en combinaison avec pembrolizumab pour le cancer du poumon non à petites cellules et le cancer de la tête et du cou
- Des essais de phase 2 en tant que traitement néoadjuvant et adjuvant pour le mélanome et le cancer de la tête et du cou résécables
La reconnaissance par Fast Company souligne le potentiel d'IO Biotech à transformer le paradigme du traitement oncologique avec des produits conçus pour être disponibles au moment du diagnostic.
IO Biotech (Nasdaq: IOBT) wurde als das neuntinnovativste Unternehmen im Bereich Biotechnologie auf der Liste Fast Companys World's Most Innovative Companies of 2025 anerkannt. Das biopharmazeutische Unternehmen in der klinischen Phase erhielt diese Auszeichnung für seinen innovativen Ansatz zu immunmodulatorischen Krebsimpfstoffen.
Die T-win® Plattform des Unternehmens entwickelt sofort einsatzbereite therapeutische Krebsimpfstoffe, die darauf abzielen, sowohl Tumorzellen als auch immununterdrückende Zellen im Tumormikroumfeld zu töten. Ihr Hauptkandidat, Cylembio®, befindet sich derzeit in:
- Eine globale Phase-3-Studie für fortgeschrittenes Melanom, mit der primären Ergebnisveröffentlichung, die für das dritte Quartal 2025 erwartet wird
- Phase-2-Studien in Kombination mit Pembrolizumab für nicht-kleinzelliges Lungenkarzinom und Kopf-Hals-Krebs
- Phase-2-Studien als neoadjuvante und adjuvante Behandlung für resektables Melanom und Kopf-Hals-Krebs
Die Anerkennung durch Fast Company hebt das Potenzial von IO Biotech hervor, das Paradigma der Onkologiebehandlung mit Produkten zu transformieren, die zum Zeitpunkt der Diagnose verfügbar sein sollen.
- None.
- None.
– Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines –
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. Fast Company recognizes 609 organizations across 58 sectors and regions. IO Biotech has been recognized for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted list as the 9th most innovative company in the world in the biotechnology category.
This notable distinction reflects IO Biotech’s relentless pursuit of pioneering off-the-shelf cancer vaccines that have the potential to change the oncology treatment paradigm with a product candidate that is designed to be available when a patient receives their diagnosis. Recognized for its innovative, T-win® platform, IO Biotech’s broadly applicable investigational therapeutic cancer vaccines are designed to target and kill both tumor cells and immune-suppressive cells in the tumor microenvironment, and lead to improved patient outcomes.
The World’s Most Innovative Companies is Fast Company's hallmark franchise and one of its most highly anticipated editorial features of the year. To determine honorees, Fast Company’s editors and writers review companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world.
"At IO Biotech, our innovative T-win platform exemplifies our commitment to developing off-the-shelf therapeutic cancer vaccines that are designed to not only target tumors and immune-suppressive cells but also change the tumor microenvironment to enhance anti-tumor activity,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. “Being recognized by Fast Company as one of the world’s most innovative biotech companies underscores the potential impact of our approach to cancer treatment, and we are deeply honored to be acknowledged for driving real innovation in oncology with the goal of improving patient outcomes.”
“Our list of the Most Innovative Companies offers both a comprehensive look at innovation today and a playbook for the future,” said Fast Company editor-in-chief Brendan Vaughan. “This year, we recognize companies that are harnessing AI in deep and meaningful ways, brands that are turning customers into superfans by overdelivering for them, and challengers that are introducing bold ideas and vital competition to their industries. At a time when the world is rapidly shifting, these companies are charting the way forward.”
IO Biotech’s lead investigational cancer vaccine candidate, Cylembio® (imsapepimut and etimupepimut, adjuvanted), is currently in a global Phase 3 clinical trial for advanced melanoma. The primary endpoint readout is anticipated in the third quarter of this year. The company is also conducting two additional, Phase 2 clinical trials with Cylembio in combination with pembrolizumab in advanced non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN), and as neoadjuvant and adjuvant treatment in patients with resectable melanoma or SCCHN.
The full list of Fast Company’s Most Innovative Companies honorees can now be found at fastcompany.com. It will also be available on newsstands beginning March 25.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead investigational cancer vaccine candidate, Cylembio® (imsapepimut and etimupepimut, adjuvanted) also known as IO102-IO103 in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
Cylembio is a trademark of IO Biotech ApS.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing or outcome of primary analysis of the company’s Phase 3 trial, other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Edelman
917-498-1967
Julie.Funesti@Edelman.com
FAQ
What is IO Biotech's (IOBT) ranking in Fast Company's Most Innovative Companies 2025?
When will IO Biotech (IOBT) release Phase 3 trial results for Cylembio?
What types of cancer is IO Biotech's (IOBT) Cylembio being tested for?
How does IO Biotech's (IOBT) T-win platform technology work?
What makes IO Biotech's (IOBT) cancer vaccine approach innovative?
